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The location of osteomyelitis is very important in Charcot neuroarthropathy (CN), especially when a
physician is considering amputation of the affected extremity.
In diabetic CN, the presence of osteomyelitis is likely. Thus, to identify the infected tissue that needs to
be removed, the speciﬁc area of infection must be correctly identiﬁed. Both CN and osteomyelitis have
high mortality rates, but osteomyelitis is more life threatening and needs aggressive treatment.
We propose a QD-based method for distinguishing CN with sterile inﬂammation from osteomyelitis
that does not require multiple and frequent imaging modalities. The method utilizes two different
colored QDs (i.e., red and green). The red QD is attached to a UBI, an antimicrobial peptide, which attaches
to bacteria, enabling their detection. The green QD is attached to MDP, which accumulates in areas of
inﬂammation. When these QDs are injected intravenously at the same time, the red QD-UBI accumulates
in infected areas and attaches to bacteria, and the green QD-MDP accumulates both in areas with sterile
inﬂammation and infected areas.
The accumulation of only green QDs in the suspect extremity signiﬁes a sterile inﬂammation process
(CN). However, the accumulation of both the red and green QDs signify infectious and inﬂammation
processes (i.e., osteomyelitis or a soft tissue infection, depending on the location). In the latter case,
the treatment needs to be more intensive, with even amputation considered.
 2015 Elsevier Ltd. All rights reserved.Introduction
Diabetes is one of the most common diseases in the world, and
its prevalence is increasing rapidly. According to a report by the
American Diabetes Association, the number of diabetic patients
in the U.S. increased from 25.8 million in 2010 to 29.1 in 2012
[1]. Diabetes is not a curable disease, but it can be managed to
prevent serious consequences, such as neuropathy, retinopathy,
diabetic nephropathy, gastric paresis, cardiovascular disease,
hypertension, and infections [2].
Osteomyelitis
Osteomyelitis of the foot in diabetic patients is largely a
consequence of several diabetes-related complications, especiallyneuropathy, and, to a lesser degree, vasculopathy and defects in
immunity and wound healing [3]. In osteomyelitis, the infarcted
part of the foot (usually the forefoot or a toe) is dull red and
diffusely swollen and warm. It may also be discharging pus or frag-
ments of bone. Systemic signs of disease, such as fever and malaise,
are unusual with foot infections, including osteomyelitis [4–10]. A
clinical examination may lead to a suspicion of osteomyelitis, but
further evaluation is needed to conﬁrm the disease. If bone can
be felt with the tip of a sterile metal probe inserted in the wound
(probe-to-bone test), then bone infection (deﬁned histologically) is
likely. The probe-to-bone test has a sensitivity of only 66%, but it is
relatively speciﬁc (84%) and has a negative predictive value of 62%.
Laboratory ﬁndings, such as leukocytosis, and tests of ESR and CRP,
which are increased in osteomyelitis, are useful in the diagnosis. A
study showed that ESR higher than 70 mm/h indicated bone infec-
tion, with 100% speciﬁcity and 50% sensitivity [5]. Imaging modali-
ties are also helpful in the diagnosis of osteomyelitis. Plain X-rays
have poor sensitivity in the early stages of the disease [6]. In con-
trast, 99mTc-diphosphonate can demonstrate abnormal uptake as
long as 2 weeks before abnormalities are seen on plain radiographs
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active bone turnover, the accumulation of labeled leukocytes is
relatively speciﬁc for infection, especially in cases where other
osseous abnormalities are present [7]. Tc-UBI, a Tc-labeled cationic
antimicrobial peptide derived from ubiquicidin, binds strongly to
microorganisms [8]. Akhtar et al. showed that the sensitivity,
speciﬁcity, and overall diagnostic accuracy of TC-UBI 29-41 in
infection localization were 100%, 80%, and 94%, respectively. The
positive and negative predictive values of TC-UBI 29-41 were
92.9% and 100%, respectively [9]. In previous study, the accuracy
of a 99m Tc-UBI scan in the diagnosis of osteomyelitis was very
high [9].
MRI has an important role in the diagnosis of osteomyelitis.
Marrow edema associated with inﬂammation is responsible for
the characteristic changes seen in MRI of osteomyelitis. The
diagnostic sensitivity of MRI for osteomyelitis has generally
been reported to be 90–100%. Its speciﬁcity is somewhat limited
due to the difﬁculty in MRI distinguishing osteomyelitis from
other causes of marrow edema, including acute neuropathic
osteoarthropathy [10–12].
A bone biopsy in diabetic patients with suspected osteomyelitis
can be done. However, it is an expensive procedure, requires
experience and technical skills, and takes several days to process
[13]. It may also yield false negative results, either because of
patchy infectious involvement or because of previous antibiotic
therapy [10].
Osteomyelitis is a difﬁcult infection to treat, largely because of
limited blood ﬂow in bone. As relapsing or repeated infections are
common in diabetic foot osteomyelitis, surgical resection of the
infected bone is often necessary [3,14].Diabetic Charcot neuroarthropathy
Charcot neuroarthropathy (CN) is a condition affecting the
bones, joints, and soft tissues of the foot and ankle, and it is
characterized by inﬂammation in the earliest phases [15]. The
clinical presentation and imaging ﬁndings of CN are challenging,
as they are very similar to those of osteomyelitis. Both CN and
osteomyelitis can coexist in an extremity, making the diagnosis
even harder [16–19].
The sensitivity and speciﬁcity (<50%) of plain radiography in
detecting early-stage CN are low [20]. Technetium-99mmethylene
diphosphonate 99m (TC-MDP) is positive in all three stages of CN
and reﬂects the increased turnover of bone [20,21]. 99m TC and
111In-WBC do not accumulate at sites of new bone formation
without infection [21]. MRI is the most sensitive modality in
detecting early changes in CN, with 90–100% sensitivity and
40–100% speciﬁcity [21–25].
The treatment aim in CN is to arrest the acute process to
prevent the development of permanent deformity and to relieve
pain, mostly by conservative treatment [26–28].Quantum dots (QDs)
Quantum dots (QDs), tiny light-emitting particles at the
nanometer scale, are emerging as a new class of ﬂuorescent probe
for in vivo bimolecular and cellular imaging [29]. QDs are extre-
mely uniform, possess a high surface to volume ratio, and are
endowed with intrinsic ﬂuorescent properties, including very
bright intensity and photostability. Moreover, the intermittent
ﬂuorescence emission (optical blinking) and electron dense nature
of QD nanoparticles allow for easy identiﬁcation of individualnanoparticles in cell preparations [30,31]. In vitro applications of
QDs are bimolecular tracking in cells, cellular imaging, and tissue
staining. In vivo applications of QDs are biodistribution [32],
vascular imaging [33], QD tracking [34], and tumor imaging [35].
With the development of biomarkers in cell biology, the track-
ing of some speciﬁc cells (such as cancer cells) becomes possible.
Gac et al. have successfully detected apoptotic cells by conjugating
QDs with biotinylated Annexin V, which enables the functionalized
QDs to bind to phosphatidylserine (PS) moieties present on the
membrane of apoptotic cells but not on healthy or necrotic cells
[36]. Liu et al. reported the development of Gd-doped ZnO QDs
with enhanced yellow ﬂuorescence, and these QDs can be used
as nanoprobes for quick cell detection with very low toxicity
[37]. In 2007, Bagalkot et al. reported a more complex QDs-
aptamer- (Apt-) doxorubicin (Dox) conjugate system [QD-
Apt(Dox)] to endow QDs with the capability of targeting, imaging,
therapy, and sensing the prostate cancer cells that express the
prostate-speciﬁc membrane antigen (PSMA) protein [38].
In addition to their usage as nanoprobes and labels for in vitro
imaging, QDs have also been widely used as in vivo imaging agents.
Cancer-speciﬁc antibody, coupled to near-IR QDs with polymer
coatings is the most popular QDs agent for tumor targeted imaging
[39]. One study used nude mice for in vivo imaging after near-IR
QD800-labeled BcaCD885 cells (BcaCD885/QD800) being
implanted. Fluorescence signals of QDs accumulated in the tumor
could be detected after 16 days of incubation at certain concentra-
tions. It suggested that, compared with CT and MRI, QD800-based
imaging could efﬁciently increase the sensitivity of early diagnosis
of cancer cells [40].Hypothesis: QD-based method for distinguishing CN and
osteomyelitis
Due to the similar clinical presentation of CN and osteomyelitis
and their similar imaging ﬁndings, the diseases are not easily
distinguishable, but they require different management and
treatment.
The location of osteomyelitis is very important in CN, especially
when a physician is considering amputation of the affected
extremity.
In diabetic CN, the presence of osteomyelitis is likely. Thus, to
identify the infected tissue that needs to be removed, the speciﬁc
area of infection must be correctly identiﬁed. Both CN and
osteomyelitis have high mortality rates, but osteomyelitis is more
life threatening and needs aggressive treatment.
We propose a QD-based method for distinguishing CN with
sterile inﬂammation from osteomyelitis that does not require mul-
tiple and frequent imaging modalities (Fig. 1). The method utilizes
two different colored QDs (i.e., red and green). The red QD is
attached to a UBI, an antimicrobial peptide, which attaches to
bacteria, enabling their detection. The green QD is attached to
MDP, which accumulates in areas of inﬂammation. When these
QDs are injected intravenously at the same time, the red QD-UBI
accumulates in infected areas and attaches to bacteria, and
the green QD-MDP accumulates both in areas with sterile
inﬂammation and infected areas.
The accumulation of only green QDs in the suspect extremity
signiﬁes a sterile inﬂammation process (CN). However, the accu-
mulation of both the red and green QDs signify infectious and
inﬂammation processes (i.e., osteomyelitis or a soft tissue infec-
tion, depending on the location). In the latter case, the treatment















































Fig. 1. QD-based method for distinguishing CN and osteomyelitis.
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